JZUS - Journal of Zhejiang University SCIENCE

Journal of Zhejiang University SCIENCE B 2014 Vol.15 No.8 P.713-719

Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma*

Author(s): Yi-lei Zhao¹, Qing-qu Guo², Gen-ren Yang¹, Qi-dong Wang¹
Affiliation(s): 1. Department of Radiology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; more
Corresponding email(s): quguoqing1973@163.com
Key Words: Hepatocellular carcinoma, Sorafenib, Apparent diffusion coefficient, Magnetic resonance imaging (MRI)

Share this article to： More <<< Previous Article \|Next Article >>>

Abstract: Objective: The relationship between apparent diffusion coefficient (ADC) and chemotherapy has been established. However, whether ADC could be considered as a measure for monitoring response to sorafenib in hepatocellular carcinoma (HCC) has not been demonstrated. This study was to investigate the ADC changes of advanced HCC under sorafenib treatment. Methods: Athymic mice with HepG2 xenografts were allocated to two groups: control and sorafenib (40 mg/kg, bid). T2 and diffusion images were acquired at each time point (0, 10, 14, and 18 d post-therapy). Tumor volume and changes in ADC were calculated. Results: Tumor volumes on Days 10, 14, and 18 after treatment showed significant decreases in the sorafenib-treated group compared with the control. Pretreatment ADC values were not significantly different between the control and treated groups. A slow increase in ADC in the peripheral zone of tumors appeared in the treated group, which was significantly higher compared with the control group on Days 10, 14, and 18. In the central part of tumors on Day 10 after treatment, an increase in ADC appeared in the treated and control groups, the ADC of the control group being significantly lower compared with the treated tumors. From Day 10 to Day 14, the ADC map showed a progressive decrease in the central region of tumors in the treated and control groups. However, this change is more significant in the treated groups. Conclusions: Early changes in mean ADC correlated with sorafenib treatment in HCC, which are promising indicators for predicting sorafenib response in this carcinoma.

磁共振弥散加权成像对索拉菲尼治疗肝细胞癌的疗效评估

研究目的：应用磁共振弥散加权成像（DWI）监测荷瘤裸鼠肝细胞性肝癌表观弥散系数（ADC）的变化，探讨ADC对索拉菲尼治疗肝细胞性肝癌的疗效预测。
创新要点：探讨磁共振DWI对索拉菲尼治疗肝癌疗效的早期评估，期望能够指导临床合理用药。
研究方法：荷瘤裸鼠分成两组（治疗组和对照组）共40只，使用GE3.0T磁共振成像系统和小动物线圈，分别于服药前后1、10、14和18天（40mg/kg，一天两次）进行T1加权成像（T1WI）、T2加权成像（T2WI）和DWI扫描。在弥散加权图像上进行ADC测量，对比不同区域和不同时间点的差异。
重要结论：索拉菲尼治疗10天后，伴随肝癌肿瘤的缩小，肿瘤内部ADC值明显上升，病理切片显示治疗组瘤体中心小血管闭塞，凋亡细胞可见，此时瘤体内坏死细胞并未大量显现，说明ADC值的改变可以反映索拉菲尼的疗效。
肝细胞癌；索拉菲尼；表观弥散系数；磁共振成像

References

[1] Armitage, P.A., Schwindack, C., Bastin, M.E., 2007. Quantitative assessment of intracranial tumor response to dexamethasone using diffusion, perfusion and permeability magnetic resonance imaging. Magn Reson Imaging, 25(3):303-310.

[2] Bruix, J., Sherman, M., 2005. Management of hepatocellular carcinoma. Hepatology, 42(5):1208-1236.

[3] Chinnaiyan, A.M., Prasad, U., Shankar, S., 2000. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. PNAS, 97(4):1754-1759.

[4] Dzik-Jurasz, A., Domenig, C., George, M., 2002. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet, 360(9329):307-308.

[5] Galons, J.P., Altbach, M.I., Paine-Murrieta, G.D., 1999. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia, 1(2):113-117.

[6] Hall, D.E., Moffat, B.A., Stojanovska, J., 2004. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res, 10(23):7852-7859.

[7] Heijmen, L., Verstappen, M.C., ter Voert, E.E., 2012. Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use?. Crit Rev Oncol Hematol, 83(2):194-207.

[8] Jain, R.K., 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307(5706):58-62.

[9] Kudo, M., 2008. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology, 75(Suppl. 1):1-12.

[10] Llovet, J.M., Burroughs, A., Bruix, J., 2003. Hepatocellular carcinoma. Lancet, 362(9399):1907-1917.

[11] Llovet, J.M., Ricci, S., Mazzaferro, V., 2008. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359(4):378-390.

[12] Low, R.N., Gurney, J., 2007. Diffusion-weighted MRI (DWI) in the oncology patient: value of breathhold DWI compared to unenhanced and gadolinium-enhanced MRI. J Magn Reson Imaging, 25(4):848-858.

[13] Lyng, H., Haraldseth, O., Rofstad, E.K., 2000. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med, 43(6):828-836.

[14] Moffat, B.A., Hall, D.E., Stojanovska, J., 2004. Diffusion imaging for evaluation of tumor therapies in preclinical animal models. MAGMA, 17(3-6):249-259.

[15] Moffat, B.A., Chenevert, T.L., Lawrence, T.S., 2005. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. PNAS, 102(15):5524-5529.

[16] Provenzale, J.M., Mukundan, S., Barboriak, D.P., 2006. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology, 239(3):632-649.

[17] Ross, B.D., Moffat, B.A., Lawrence, T.S., 2003. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther, 2(6):581-587.

[18] Seierstad, T., Folkvord, S., Roe, K., 2007. Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice. Neoplasia, 9(5):392-400.

[19] Thoeny, H.C., de Keyzer, F., Chen, F., 2005. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology, 234(3):756-764.

[20] Wilhelm, S.M., Carter, C., Tang, L., 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64(19):7099-7109.

[21] Zhao, M., Pipe, J.G., Bonnett, J., 1996. Early detection of treatment response by diffusion-weighted ¹H-NMR spectroscopy in a murine tumour in vivo . Br J Cancer, 73(1):61-64.

Similar articles

- Go to

磁共振弥散加权成像对索拉菲尼治疗肝细胞癌的疗效评估

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

References